PMID: 11926785Apr 3, 2002Paper

Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial

Annals of Internal Medicine
C G FanelliG B Bolli

Abstract

Intensive insulin treatment of type 1 diabetes mellitus increases the risk for nocturnal hypoglycemia. To demonstrate that splitting the evening insulin regimen reduces the risk for nocturnal hypoglycemia in intensive treatment of type 1 diabetes mellitus. Randomized, open, two-treatment crossover trial in two 4-month periods. University research center in Italy. 22 C-peptide-negative persons with type 1 diabetes mellitus (mean age [+/-SD], 29 +/- 3 years). Each patient was randomly assigned to one of two insulin regimens for 4 months and then switched to the other regimen for another 4 months. The two treatment regimens were 1) mixed treatment--a mixture of human regular and neutral protamine Hagedorn (NPH) insulin administered before dinner and 2) split treatment--human regular insulin administered at dinner and NPH insulin administered at bedtime. Frequency of nocturnal hypoglycemia. Secondary end points were levels of fasting blood glucose and hemoglobin A1c and responses to experimental hypoglycemia. During the split-regimen treatment period, patients had fewer episodes of nocturnal hypoglycemia (mean [+/-SE], 0.10 +/- 0.02 episode/patient-day vs. 0.28 +/- 0.04 episode/patient-day; P = 0.002), a lower fasting blood glucose...Continue Reading

Citations

Oct 26, 2005·Diabetes Technology & Therapeutics·Bruce Buckingham
Jun 1, 2006·Diabetes Technology & Therapeutics·John GerichGeremia B Bolli
Jun 28, 2011·Diabetes Technology & Therapeutics·Francesca PorcellatiCarmine G Fanelli
Dec 14, 2005·Postgraduate Medical Journal·M C Marshall
Nov 30, 2010·Best Practice & Research. Clinical Endocrinology & Metabolism·Kamila Jauch-Chara, Bernd Schultes
Nov 20, 2004·Diabetes/metabolism Research and Reviews·Carmine G FanelliGeremia B Bolli
Jul 2, 2003·Expert Opinion on Pharmacotherapy·Vincent McAulay, Brian M Frier
Dec 6, 2003·Pediatric Diabetes·Timothy W Jones, Elizabeth A Davis
Jan 13, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Kate V Allen, Brian M Frier
Jun 18, 2011·Postgraduate Medicine·Kevin D Niswender
Dec 27, 2018·Diabetic Medicine : a Journal of the British Diabetic Association·S Misra, C Mathieu
Feb 12, 2008·Revista clínica española·J Sáez de la FuenteA Herreros de Tejada López-Coterilla
Oct 29, 2021·Diabetes, Obesity & Metabolism·David R OwensGeremia B Bolli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.